GlassScriptPhysician profile
Aliya B Pasik
NPI 1578992632
$15,149.79
in general payments reported to CMS, 2019-2025
19 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $5,906 · 2023: $7,030 · 2024: $881 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,950 · Food and Beverage: $3,082 · Travel and Lodging: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,950.00 |
| Food and Beverage | $3,081.66 |
| Travel and Lodging | $887.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $11,875.06 | 2022-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $1,046.57 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $355.22 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $328.56 | 2021-2024 | Trintellix |
| Alkermes, INC. | $276.03 | 2023-2025 | Vivitrol, Aristada, Lybalvi |
| Novo Nordisk INC | $248.90 | 2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $244.71 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $176.54 | 2024-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $134.51 | 2023-2024 | Azstarys |
| Braeburn INC. | $98.00 | 2024 | Brixadi |
| Collegium Pharmaceutical, INC. | $63.26 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $58.23 | 2024-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $46.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.87 | 2023-2024 | Spravato |
| Abbvie INC. | $42.41 | 2021-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $38.70 | 2025 | Fanapt |
| Indivior INC. | $34.15 | 2024 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $20.79 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Pasik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.